Treatment Of Moderate To Severe Vasomotor Symptoms Associated With Menopause — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for treatment of moderate to severe vasomotor symptoms associated with menopause. 1 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
1
Active US patents
85/100
Avg vulnerability
—
Annual revenue covered

Originators in Treatment Of Moderate To Severe Vasomotor Symptoms Associated With Menopause

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer Inc. 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating treatment of moderate to severe vasomotor symptoms associated with menopause. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
27

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Duavee
Bazedoxifene Acetate
 Pfizer Inc. 1 85 — 2027-03-10

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7683051 Duavee method of use 85 2027-03-10

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7683051 Duavee method of use 85 2027-03-10

Related